{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:34:36Z","timestamp":1780641276787,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil\/folinic acid (nal-IRI\u2009+\u20095-FU\/LV). However, there have been no studies comparing nal-IRI\u2009+\u20095-FU\/LV therapy with S-1 monotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The main objective of this study was to compare overall survival (OS) in patients treated with nal-IRI\u2009+\u20095-FU\/LV and those treated with S-1 monotherapy as second-line treatments, using the inverse probability of treatment weighting (IPTW) method. This study was conducted in 31 institutions participating in Japan Oncology Network in Hepatobiliary and Pancreas. To minimize potential biases due to the retrospective design, IPTW analysis was performed with multiple imputation, and imputed IPTW-adjusted hazard ratios and corresponding 95% confidence intervals (CIs) were estimated using a Cox proportional hazards model and combined into pooled estimates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 463 metastatic PC patients were enrolled in this study (257 in the S-1 monotherapy group and 206 in the nal-IRI\u2009+\u20095-FU\/LV group). The median OS was 7.50\u00a0months (95% CI 4.18\u201312.69\u00a0months) in the nal-IRI\u2009+\u20095-FU\/LV group and 5.72\u00a0months (95% CI 2.76\u201310.79\u00a0months) in the S-1 monotherapy group. In the IPTW-adjusted Cox proportional hazards model, nal-IRI\u2009+\u20095-FU\/LV was associated with a significant OS benefit (pooled IPTW-adjusted hazard ratio, 0.779; 95% CI 0.399\u20140.941; <jats:italic>p<\/jats:italic>\u2009=\u20090.025).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings support the use of nal-IRI\u2009+\u20095-FU\/LV as standard second-line treatment for PC patients after gemcitabine-based chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-024-02186-9","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:02:00Z","timestamp":1732968120000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of liposomal irinotecan\u2009+\u20095-FU\/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-0095","authenticated-orcid":false,"given":"Hiroshi","family":"Imaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nakachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gou","family":"Murohisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Asagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Nebiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Shioji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japan Oncology Network in Hepatobiliary and Pancreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"issue":"3","key":"2186_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2186_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S160018","volume":"10","author":"W Wu","year":"2018","unstructured":"Wu W, et al. Rising trends in pancreatic cancer incidence and mortality in 2000\u20132014. Clin Epidemiol. 2018;10:789\u201397.","journal-title":"Clin Epidemiol"},{"key":"2186_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2019.11.002","volume":"125","author":"AEJ Latenstein","year":"2020","unstructured":"Latenstein AEJ, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83\u201393.","journal-title":"Eur J Cancer"},{"issue":"9791","key":"2186_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, et al. Pancreatic cancer. The Lancet. 2011;378(9791):607\u201320.","journal-title":"The Lancet"},{"issue":"1","key":"2186_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"2186_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"2186_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"2186_CR8","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","volume":"34","author":"A Ohba","year":"2023","unstructured":"Ohba A, et al. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II\/III trial. Ann Oncol. 2023;34:S894.","journal-title":"Ann Oncol"},{"issue":"23","key":"2186_CR9","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"},{"issue":"32","key":"2186_CR10","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, et al. PANCREOX: A Randomized Phase III Study of Fluorouracil\/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320.","journal-title":"J Clin Oncol"},{"issue":"10018","key":"2186_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"27","key":"2186_CR12","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38(27):3217\u201330.","journal-title":"J Clin Oncol"},{"key":"2186_CR13","doi-asserted-by":"crossref","unstructured":"Conroy, T., et al., Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2023.","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"2186_CR14","first-page":"2023","volume":"1","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2024","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma Version. 2024;1:2023.","journal-title":"Pancreatic Adenocarcinoma Version."},{"issue":"9","key":"2186_CR15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/bjc.2015.103","volume":"112","author":"S Ohkawa","year":"2015","unstructured":"Ohkawa S, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015;112(9):1428\u201334.","journal-title":"Br J Cancer"},{"issue":"4","key":"2186_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/bjc.2016.436","volume":"116","author":"T Ioka","year":"2017","unstructured":"Ioka T, et al. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2017;116(4):464\u201371.","journal-title":"Br J Cancer"},{"key":"2186_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.10.004","volume":"106","author":"T Ioka","year":"2019","unstructured":"Ioka T, et al. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer. 2019;106:78\u201388.","journal-title":"Eur J Cancer"},{"issue":"24","key":"2186_CR18","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno M, et al. nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med. 2020;9(24):9396\u2013408.","journal-title":"Cancer Med"},{"issue":"4","key":"2186_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28(4):493\u2013511.","journal-title":"Int J Clin Oncol"},{"key":"2186_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2015.11.002","volume":"54","author":"H Imaoka","year":"2016","unstructured":"Imaoka H, et al. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial. GEST study Eur J Cancer. 2016;54:96\u2013103.","journal-title":"GEST study Eur J Cancer."},{"issue":"13","key":"2186_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640\u20138.","journal-title":"J Clin Oncol"},{"key":"2186_CR22","doi-asserted-by":"crossref","unstructured":"Rubin, D.B., Multiple Imputation for Nonresponse in Surveys. Wiley Series in Probability and Statistics. 1987: John Wiley & Sons, Inc.","DOI":"10.1002\/9780470316696"},{"key":"2186_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","volume":"9","author":"A Marshall","year":"2009","unstructured":"Marshall A, et al. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2186_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/10705510802339072","volume":"15","author":"TE Bodner","year":"2008","unstructured":"Bodner TE. What Improves with Increased Missing Data Imputations? Struct Equ Modeling. 2008;15(4):651\u201375.","journal-title":"Struct Equ Modeling"},{"issue":"4","key":"2186_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"key":"2186_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338: b2393.","journal-title":"BMJ"},{"issue":"6","key":"2186_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/jep.12254","volume":"20","author":"A Linden","year":"2014","unstructured":"Linden A. Combining propensity score-based stratification and weighting to improve causal inference in the evaluation of health care interventions. J Eval Clin Pract. 2014;20(6):1065\u201371.","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"2186_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jclinepi.2014.08.011","volume":"68","author":"MS Ali","year":"2015","unstructured":"Ali MS, et al. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. J Clin Epidemiol. 2015;68(2):122\u201331.","journal-title":"J Clin Epidemiol"},{"key":"2186_CR29","unstructured":"Greifer, N., WeightIt: Weighting for Covariate Balance in Observational Studies. 2023(R package version 0.14.2)."},{"key":"2186_CR30","doi-asserted-by":"crossref","unstructured":"Pishgar, F., et al., MatchThem:: Matching and Weighting after Multiple Imputation. The R Journal, 2021. 13(2).","DOI":"10.32614\/RJ-2021-073"},{"key":"2186_CR31","unstructured":"Greifer, N., cobalt: Covariate Balance Tables and Plots. 2023(R package version 4.5.1.)."},{"issue":"2","key":"2186_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100049","volume":"6","author":"HS Park","year":"2021","unstructured":"Park HS, et al. Liposomal irinotecan plus fluorouracil\/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open. 2021;6(2): 100049.","journal-title":"ESMO Open."},{"issue":"2","key":"2186_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","volume":"63","author":"C Morizane","year":"2009","unstructured":"Morizane C, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63(2):313\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2186_CR34","doi-asserted-by":"crossref","unstructured":"Berger, J.M., et al., Prognosticators of survival in patients with metastatic pancreatic cancer and ascites. ESMO Open, 2023. 8(6).","DOI":"10.1016\/j.esmoop.2023.102048"},{"key":"2186_CR35","doi-asserted-by":"crossref","unstructured":"Inoue, K., et al., Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Pancreatology, 2024.","DOI":"10.1016\/j.pan.2024.03.015"},{"issue":"8","key":"2186_CR36","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979\u201385.","journal-title":"Ann Oncol"},{"issue":"2","key":"2186_CR37","first-page":"105","volume":"8","author":"S Sugawara","year":"2023","unstructured":"Sugawara S, et al. Guidelines for Central Venous Port Placement and Management (Abridged Translation of the Japanese Version). Interv Radiol (Higashimatsuyama). 2023;8(2):105\u201317.","journal-title":"Interv Radiol (Higashimatsuyama)."},{"issue":"10298","key":"2186_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(21)00766-2","volume":"398","author":"JG Moss","year":"2021","unstructured":"Moss JG, et al. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet. 2021;398(10298):403\u201315.","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1007\/s00535-025-02215-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02186-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:16:03Z","timestamp":1741086963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02186-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02186-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00535-025-02215-1","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access order.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00535-025-02215-1","URL":"https:\/\/doi.org\/10.1007\/s00535-025-02215-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroshi Imaoka has received research funding from Ono Pharmaceutical, Servier, Novartis, and Boehringer Ingelheim; and honoraria from Servier and Novartis. Masafumi Ikeda has received research funding from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Chiome Bioscience, Delta-Fly Pharma, Eisai, Eli Lilly Japan, Invitae, MSD, J-Pharma, Merck biopharma, Merus N.V., Novartis, Servier, Ono Pharmaceutical, Pfizer, and Syneos Health; and honoraria from AbbVie, AstraZeneca, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Fujifilm Toyama Chemical, Guardant Health Japan, Incyte Biosciences Japan, MSD, Servier, Novartis, Nippon Kayaku, Ono Pharmaceutical, Taisho Pharmaceutical, Teijin, Takeda, Taiho Pharmaceutical, and Yakult Honsha; and is a member of advisory board for AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, MSD, and Servier. Satoshi Kobayashi has received honoraria from AstraZeneca, Eli Lilly, Boston Scientific, Taiho, Daiichi Sankyo, and Yakult Honsha. Yasuyuki Kawamoto has received research funding from Takeda. Noritoshi Kobayashi has received research funding from Novartis; and honoraria from Novartis, Teijin Pharma, Teijin Healthcare, EA Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Yakult Honsha, MSD, and PD Radiopharma (successor to the radiopharmaceutical business of Fujifilm Toyama Chemical). Naohiro Okano has received honoraria from AstraZeneca. Kumiko Umemoto has received honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical, Novartis and Yakult Honsha. Ayumu Hosokawa has received honoraria from Ono Pharmaceutical and Daiichi Sankyo. Hiroyuki Okuyama has received honoraria from Novartis and AstraZeneca. Satoshi Shimizu has received research funding from AstraZeneca, Incyte, Delta-Fly Pharma, and Servier. Chigusa Morizane has received research funding from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, AstraZeneca, Merck, Daiichi Sankyo, Boehringer Ingelheim, Eisai, Daiichi Sankyo RD Novare, Labcorp, Hitachi, and MSD; and honoraria from Novartis, Yakult Honsha, Servier, Taiho Pharmaceutical, Eisai, MSD, AstraZeneca, TORAY, Guardant, and Myriad Genetics; and is a member of advisory board for Yakult Honsha, MSD, Servier, Boehringer Ingelheim, Taiho, Novartis, AstraZeneca, MSD, Servier, and Merck. Makoto Ueno has received research funding from Astellas Pharma, AstraZeneca, Chiome Bioscience, Chugai Pharmaceutical, DFP,\u00a0Eisai, Incyte, J-pharma, MSD, Novartis, Novocure, Ono Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, and Servier; and honoraria from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Incyte, J-pharma, MSD, Servier, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Boehringer Ingelheim, and Yakult Honsha. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}